Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Congressional Dems Generating Heat, But No Hearings, On Rx Prices

This article was originally published in The Pink Sheet Daily

Executive Summary

House oversight committee Democrats want to subpoena Valeant Pharmaceuticals and hold a hearing with Turing Pharmaceuticals on drug price increases. Their requests may have more impact on investors than committee leadership, as the company saw a same-day stock decrease of 16%.

You may also be interested in...



Senate's Bipartisan Rx Pricing Probe Seeks Documents Regarding FDA Regs

Probe launched by the Senate Aging panel asks four manufacturers – Valeant, Turing, Retrophin and Rodelis – for documents pertaining to pricing their products, but also wants to know how they may have analyzed FDA regs to help them avoid competition.

HHS Raises Profile In Drug Costs Discussion

On Nov. 20, HHS will host a day-long forum on pharmaceuticals, including a look at high-cost specialty drugs and innovative purchasing strategies.

PhRMA Takes Aim At Valeant In Defense Of Drug Pricing By ‘Innovative’ Firms

The strategy of publicly criticizing pharmaceutical companies, albeit non-members, is an unusual one for PhRMA. But it demonstrates the group’s interest in playing offense, and not just defense, in the drug price debate.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS078962

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel